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ABSTRACT 
Objectives: 
Borderline personality disorder (BPD) is characterised by recurring crises, hospitalizations, 
self-harm, suicide attempts, addictions, episodes of depression, anxiety and aggression and 
lost productivity. The objective of this study is to determine the use of direct health care 
resources by persons with BPD in Ireland and the corresponding costs. 
 
Methods: 
This prevalence-based micro-costing study was undertaken on a sample of 196 individuals 
with BPD attending publicly funded mental health services in Ireland. All health care costs 
were assessed using a resource utilisation questionnaire completed by mental health 
practitioners. A probabilistic sensitivity analysis, using a Monte Carlo simulation, was 
performed to examine uncertainty.  
 
Results: 
Total direct health-care cost per individual was €10,844 annually (ranging from 5,228 to 
20,609). Based on a prevalence of 1% and an adult population (18-65yrs) of 2.87 million, we 
derived that there were 28,725 individuals with BPD in Ireland. Total yearly cost of illness 
was calculated to be up to €311.5 million.  The absence of productivity loss data (e.g. 
absenteeism and presenteeism), non-health care costs (e.g. addiction treatment), and indirect 
costs (e.g. informal care) from study participants is a limitation of this study. 
 
Conclusions: 
There is a dearth of data on health care resource use and costs of community mental health 
services in Ireland. The absence of this data is a considerable constraint to research and 
decision-making in the area of community mental health services. This paper contributes to 
the limited literature on resource use and costs in community mental health services in 
Ireland. 
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1. INTRODUCTION  
Borderline personality disorder (BPD) is a mental health diagnosis characterised by a 
pervasive pattern of instability of interpersonal relationships, self-image, affect, and marked 
impulsivity (American Psychiatric Association, 2005). BPD is typically characterised by 
patterns of cognitive, emotional and behavioural dysregulation that often manifests in self-
harm and suicidal behaviours (Kuo et al., 2006).  BPD can be a life-threatening mental health 
condition estimated to be present in 0.7% to 1% of the general population (Coid et al., 2006, 
Jackson and Burgess, 2004, Torgersen et al., 2001). Individuals with a BPD diagnosis 
typically exhibit self-harming behaviours, with lifetime rates of approximately 70% for acts 
of self-injury, 80% for suicide attempts, and 10% for suicide reported. As a result, quality of 
life is found to be severely impaired in this population (Giesen-Bloo et al., 2006, Palmer et 
al., 2006). 
 
Due to the chronic nature of BPD, this client group tend to use health care resources more 
extensively than individuals with other personality disorders or with major depression 
(Bender et al., 2006, Zanarini et al., 2001). More frequent and continued use of outpatient 
and inpatient treatment and high use of prescribed psychotropic medication is reported for 
persons with BPD (Bender et al., 2006, Zanarini et al., 2001). In addition, there is a strong 
relationship between BPD and poor occupational functioning (Jackson and Burgess, 2004, 
Skodol et al., 2002). Therefore, this client group is characterised by recurring crises, 
hospitalizations, self-harm, suicide attempts, addictions, episodes of depression, anxiety and 
aggression and lost productivity, explaining why BPD is considered one of the most 
expensive mental health disorders (Soeteman et al., 2008, van Asselt et al., 2007). 
 
Recent cost-of-illness (COI) studies of BPD in Spain and the Netherlands report that BPD is 
associated with high COI, as well as indicating that the composition of costs vary 
considerably (Soeteman et al., 2008, van Asselt et al., 2007). While there are variations in the 
identification of health care and societal costs in these studies, it is apparent that national 
variations in BPD treatment exist. For example, medications accounted for 2% of total costs 
in the Netherlands (Soeteman et al., 2008) but 25% in Spain (Salvador-Carulla et al., 2014). 
This suggests variations in national treatment strategies, although clinical guidelines for BPD 
(where they exist) advocate behavioural and community support in preference to 
hospitalisation and medication (National Institute for Health and Care Excellence, 2009). 
Given these variations in practice across jurisdictions, examinations of current practice are 
required on a country-by-country basis.  
 
By the mid 2000s, procedures for recording epidemiological information about self-harm and 
suicide in Ireland had advanced (e.g. National Self-Harm Registry Ireland) (Flynn et al., 
2018a). However, the national government policy framework for mental health services and 
the national policy framework for suicide prevention activities are both over ten years old 
(Government of Ireland, 2006, Health Service Executive, 2005). While the recent succession 
policy document for suicide prevention is welcome (Health Service Executive, 2015), it is 
important that decision-making is informed by economic information, ensuring appropriate 
allocation of scarce health care resources.  
 
In 2006, the overall total economic and social cost of mental health problems in Ireland was 
estimated to be over 3 billion (O’Shea and Kennelly, 2008). However, there is a dearth of 
condition-specific COI studies on mental health disorders in Ireland, a COI of schizophrenia 
being a notable exception (Behan et al., 2008). BPD in particular, presents huge challenges 
for mental health services, and estimates suggest that it features in 11-20% of clinical 
presentations to mental health outpatient clinics in Ireland (Government of Ireland, 2006). In 
addition, it is recognised as the most difficult condition for clinicians to treat (Government of 
Ireland, 2006). This study provides insight on resource use and costs of treating BPD in 
mental health services in an Irish context, which is of considerable value in budgetary and 
service planning.  
 
 
2. METHODS 
2.1 Design 
This is a prevalence-based cost analysis study determining the direct health care costs of 
treating persons with BPD in Ireland.  
 
2.2 Setting  
Ireland’s public health service, the Health Service Executive (HSE), has responsibility for 
delivering all public health services in Ireland. There are four core areas of health service for 
the Irish population: acute hospitals, social care and disability, mental health and primary 
care. About 90% of mental health difficulties are addressed through the primary care system 
in Ireland, while the remaining patients require more specialist care which is accessed 
through mental health services (McDaid, 2013). This secondary level care for more complex 
mental health difficulties is delivered through multidisciplinary community mental health 
teams which offers specialised services for adults, children and adolescents, older people and 
intellectual disability (Government of Ireland, 2006). Multidisciplinary teams typically 
comprise of psychiatrists, clinical psychologists, social workers, community mental health 
nurses and occupational therapists. The secondary health care system was the setting for this 
study as specialist care for BPD is provided at secondary care level in Ireland.  
 
2.3 Data Collection & Sample 
At present, Ireland lacks an integrated health information system with unique patient 
identifiers. Therefore, a dedicated resource-use questionnaire was designed to capture the full 
range of secondary level care services utilised by individuals with BPD to facilitate the 
micro-costing analysis. While other resource use questionnaires exist (e.g. client socio-
demographic and service receipt inventory (CSRI)) and have previously been used in Irish 
health service studies  (Raftery et al 2017; Cronin & Bourke 2017), given that standard BPD 
care requires such a broad range of services, it was important to capture a full ‘census’ of 
services so to speak. In designing the dedicated questionnaire, expert opinion from 
community mental health practitioners were elicited to ensure the full range of services 
available nationally were captured.  
 
This study examines the cost of BPD, therefore non-BDP resource use is not collected or 
required. Information about the following resource use in the treatment of BPD was 
collected: acute hospital stay; emergency department presentation; ambulance use; number 
and duration of visits with multidisciplinary team members; type and quantity of medications.  
 
Data on resource utilisation in the treatment of BPD was extracted from participants’ clinical 
files by their lead treating clinician. This minimised recall and reliability issues, which may 
ensue if relying on self-reported resource utilisation from participants. Extracting data 
directly from participants’ files allows the researchers to be confident that each participants’ 
contact with mental health services (e.g. acute inpatient, outpatient and emergency 
department) is accurately reported. However, it is necessary to acknowledge that in the 
absence of an integrated health information system, there may be instances where utilisation 
is not recorded, for example, where participants engage with health services outside their 
primary health service (e.g. presenting to the Emergency Department in another part of the 
country). 
 
196 participants were recruited from nine geographically-dispersed adult mental health 
services in urban and rural settings across the Republic of Ireland. Participants were mental 
health service users, aged 18-64 years, who had received a diagnosis, or met criteria for a 
diagnosis of borderline personality disorder (DSM-IV) or emotionally unstable personality 
disorder (ICD-10). This paper is part of a larger study examining the effectiveness and cost-
effectiveness of Dialectical Behaviour Therapy (DBT) for treating individuals with BPD. The 
participants in this study include all recruited participants at baseline (please see Flynn et al., 
2018b for study protocol).1 Data collection occurred between February 2014 and March 
2016. Participants in this study were recruited from secondary care services at multiple 
geographically-dispersed sites across the Republic of Ireland. This sample is representative of 
the most complex individuals with a formal diagnosis and availing of specialist services. 
Therefore, the sample accurately depicts the potential costs to the health service if all 
individuals with a formal diagnosis were actively engaging with secondary level care. 
 
Of the 196 participants, 81% were female.  Ages ranged from 18-64, with 30% and 29% of 
participants in the 35-44 and 25-34 age categories respectively. 44% of participants were 
single; 18% married; 23% in a relationship and the remainder were divorced, separated or did 
                                                          
1While the study protocol refers to both adult and child/adolescent community health services users (Flynn et 
al., 2018a), this study pertains to AMHS service users. 
not specify marital status. 21% of participants were in full or part time employment, with the 
remainder being unemployed, retired or in education (see Table 1).  
 
 
Table 1 Characteristics of Study Sample  
Characteristics n % 
Gender   
Female 158 81 
Male 38 19 
Age   
18-24 years 41 21 
25-34 years 57 29 
35-44 years 58 30 
45-54 years 35 18 
55-64 years 4 2 
Did not specify 1 1 
Marital status   
Single 86 44 
In a relationship 45 23 
Married 36 18 
Separated/Divorced 27 14 
Other 2 1 
Employment status   
Full-time employment 23 12 
Part-time employment 18 9 
Student 20 10 
Retired 3 2 
Unemployed 90 46 
Other 42 21 
N= 196. Note 1: The study population includes individuals 18-64 years.  
 
 
Ethical approval to carry out this research was received from the following research ethics 
committees: Cork Research Ethics Committee of the Cork University Teaching Hospitals, 
Galway Clinical Research Ethics Committee, HSE Mid-Western Regional Hospital Research 
Ethics Committee, HSE North East Area Research Ethics Committee, HSE South East Area 
Research Ethics Committee, Naas General Hospital Ethics Committee and Sligo General 
Hospital Research Ethics Committee. All participants were provided with detailed 
information about the research study and data confidentiality. Participation in the study was 
voluntary and could be withdrawn at any time. All participants signed written informed 
consent forms (Flynn et al., 2018a).  
 
2.4 Cost Analysis 
Following Larg and Moss (2011) and Drummond et al. (2015) a micro costing approach 
employing standard methods was used to estimate the cost of treating BPD. Owing to the lack 
of national unit cost data/Ready Reckoner for community mental health services a micro 
costing approach was necessary. In undertaking the analysis, national guidelines for 
conducting cost analyses were adhered to (Health Information and Quality Authority, 2014). 
The resources used were identified and measured from the resource use questionnaire 
discussed above. The primary perspective taken was that of the health service provider and 
payer – the HSE, and included direct health care costs only. Three categories of direct health 
care costs were considered: acute care; community care and medication.  
 
To value health resource use, a variety of methods were employed in line with national 
guidelines (Health Information and Quality Authority, 2014). Diagnostic Related Group 
(DRG) estimates from the National Ready Reckoner were employed to estimate the costs of 
acute care (emergency department and acute hospitalisation) (Health Service Executive, 
2013a). In order to value the cost of ambulance transfers, an estimate from the literature was 
employed and adjusted for inflation (Gannon et al., 2007).  
 
Data on number and duration of visits to Adult Mental Health Services (AMHS) were 
provided in the resource use questionnaire. Using the hourly wage for each professional the 
value of community care services was estimated. Hourly wages were estimated using national 
guidelines (Health Information and Quality Authority, 2014), whereby the median value from 
the salary scales is adjusted for relevant costs including overheads. In the absence of evidence 
on professionals’ administration/ non-patient contact time associated with service delivery, it 
is assumed these are accounted for in the included overheads (25%).  
 
With regards to valuing medications, the resource use questionnaire provided data on type 
and quantity of medications used. To estimate cost of medications national guidelines were 
employed (National Centre for Pharmacoeconomics, 2016). The price to the wholesaler was 
extracted from the national medicine database (Primary Care Reimbursement Service, 2017); 
and the dispensing fee and rebate to the wholesaler were estimated.   
 
The resource use questionnaire provided evidence on resource utilisation for a 6 month 
period. Assuming this 6 months reflected usual practice, it was directly extrapolated to 12 
months to represent annual utilisation.  
 
2.5 Sensitivity Analysis 
In this analysis, resource estimates are from a sample of data, thus the parameters are subject 
to uncertainty (Briggs et al., 2006). To address this parameter uncertainty a probabilistic 
sensitivity analysis (PSA) was employed. This required characterising uncertainty in input 
parameters, propagating uncertainty through the model using a Monte Carlo simulation 
model and presenting the implications of parameter uncertainty on the cost estimates. Thus 
we can examine if uncertainty in the input parameters results in uncertainty surrounding the 
cost estimate. The latter is illustrated in the 95-percentile ranges presented.  
 
One-way sensitivity analyses are also employed to estimate the burden of BPD to the Irish 
health service by varying prevalence rates. Prevalence rates of BPD in the population aged 18 
to 65 (as advocated by Torgersen et al., 2001) were varied between 0.7% and 1%, in line with 
international literature (Coid et al., 2006, Jackson and Burgess, 2004, Torgersen et al., 2001). 
 
3. RESULTS 
3.1 Direct health service costs 
Acute health services utilised included emergency department attendance, ambulance transfer 
and inpatient admission. Analysis of the data revealed 45% of the sample visited the 
emergency department 2.3 times in a 6-monthly period on average. Applying the relevant 
costs, the average annual cost of emergency department visits is €717 per person with BPD. 
Approximately 18% of these visits included transfer by ambulance, at a cost of €81 per 
person with BPD. The data revealed that 37% of the sample population were admitted as an 
inpatient. Applying the relevant DRG tariff, this is valued at the annual average cost per 
person with BDP of €5,497 for inpatient care (see Table 2).  
 
All persons in the sample utilised AMHS at an annual average cost of €3,282 per person with 
BPD. These services included psychiatrists, hospital physicians, nursing personnel, clinical 
psychologists, counsellors, therapists and social workers (see Table 3).  
 
The resource use questionnaire also included questions on type and dosage of medications. 
82% of the sample population reported taking at least one medication. The annual average 
cost of medications per person with BPD was €1,267. As many persons with BPD may have 
a means tested medical card (permitting them access to medication for a €2.50 fee per item 
dispensed up to maximum of €25 at the time of the analysis (Health Service Executive, 
2013b)) reimbursement for these medications would be included in HSE budgets, thus are 
included in the analysis.  
 
The average total cost to the HSE when utilisation of acute health services, adult mental 
health services, other funded mental health services and medications are included is €10,844 
per person per year. The breakdown of these costs reveals that admissions account for 51% of 
the total direct health care costs; mental health services 30% and medications 12%. 
Emergency department visits and ambulance transfers account for 7% collectively (Table 2). 
 
3.4 Sensitivity analysis  
Within the probabilistic sensitivity analysis, a Monte Carlo simulation was conducted around 
the total cost estimate to account for uncertainty. The sensitivity analysis results indicate a 95 
percentile range for the average total costs of €5,228 to €20,609 suggesting uncertainty in the 
input parameters translates to uncertainty surrounding the cost estimate (See Table 2).  
  
 Table 2 - Average Annual Cost of BDP per person in Ireland 
 
Annual € %  
 
95 percentile range2  
DIRECT HEALTH CARE COSTS   
 
Acute Care 
  
Emergency Department 717 7% 0 10,481 
Ambulance 81 1% 0 2,194 
Hospitalisations 5,497 51% 17 31,418 
     
Adult Mental Health Services1 3,282 30% 2,852 3,434 
     
Medication 1,267 12% 436 2,036 
     
TOTAL 10,844 100% 5,228 20,609 
     
1 See Table 3 for further detail on AMHS services 
 2 Results of Probability Sensitivity Analysis (PSA) Note: beta distribution applied to 
probability of attending or using each services; Gamma distribution applied to the frequency 
and duration of visits and normal distributions applied to costs. 
  
Table 3 Utilisation of Adult Mental Health Services by Individuals with BPD 
 Probability Frequency 
 
Duration (Hrs) 
Average Std 
Dev 
Average Std 
Dev 
Consultant Psychiatrist 0.80 5.09 5.70 0.41 0.21 
Senior House Officer 0.27 4.51 7.17 0.50 0.30 
Staff Nurse 0.22 9.23 12.85 0.59 0.29 
Social Worker 0.18 4.45 5.31 0.90 0.30 
Clinical Psychologist 0.17 9.89 10.15 1.12 0.48 
Registrar Psychiatrist 0.15 5.96 7.57 0.34 0.12 
Clinical Nurse Specialist 0.15 12.19 12.21 0.93 0.36 
Senior Occupational Therapist 0.14 12.18 25.72 0.91 0.21 
Occupational Therapist 0.14 7.68 8.78 0.92 0.46 
Senior Clinical Psychologist 0.13 6.41 5.72 0.97 0.21 
Senior Registrar Psychiatrist 0.11 3.63 3.82 0.46 0.22 
Clinical Nurse Manager 0.11 7.05 6.69 0.67 0.44 
Community Mental Health Nurse 0.11 15.24 15.72 0.49 0.22 
Addiction Counsellor 0.10 11.03 7.41 0.80 0.18 
Crisis Nurse 0.08 6.93 3.43 1.26 0.40 
Senior Staff Nurse 0.07 21.08 25.91 0.48 0.23 
NCHD 0.06 5.50 5.73 0.43 0.24 
DSH Liaison Nurse 0.04 1.71 1.25 0.89 0.39 
Family Therapist 0.04 9.00 8.08 1.00 - 
Principal clinical Psychologist 0.03 1.00 - 1.00 0.44 
DSH Nurse 0.02 5.33 2.52 1.17 0.29 
Counsellor 0.02 15.67 8.50 0.89 0.10 
Alcohol Counsellor 0.02 3.00 1.41 0.92 0.12 
CBT Therapist 0.02 8.00 2.00 0.94 0.10 
Team lead social worker 0.02 4.00 2.65 0.83 0.29 
HBTT Nurse 0.01 4.00 - 0.75 - 
A&E SH Nurse 0.01 2.00 - 0.33 - 
Scan Nurse 0.01 1.50 0.71 1.00 - 
Trainee Psychologist 0.01 3.00 - 1.67 - 
Assistant Psychologist 0.01 3.00 - 2.00 - 
Social Care Worker 0.01 3.50 3.54 1.00 - 
Family support worker 0.01 3.00 1.41 2.00 - 
Notes: 1.Probability: the probability of a client attending professional. 2. Frequency: the 
number of visits to that professional in a 6 monthly period per client. 3. Durations (Hrs): the 
duration per visit, measured in hours per client. 4. Abbreviations: NCHD: Non-consultant 
hospital doctor; DSH: Deliberate self-harm; HBTT = Home based therapy team; A&E: 
accident and emergency.   
3.5 Prevalence  
Table 4 presents the estimated costs of providing health care for the BPD population using 
the previously discussed range of prevalence rates. With a 1% prevalence rate the annual cost 
of treating BPD in Ireland is €311.50 million in direct health care costs. Lowering the 
prevalence rate to 0.7% (one-way sensitivity analysis) decreases the estimated annual direct 
health care costs to €218.05 million. These COI estimates assume that all persons with BPD 
are utilising the mental health services. It is important to note that given the complexity of 
BPD, persons with the condition may not yet be diagnosed, while others with a diagnosis 
may not be engaging with the mental health services.  
 
Table 4 Total Costs (€ Millions) of BPD in Ireland 
Prevalence Estimate of persons with BPD 1 Total Health Care Costs (€m) 
 
0.7% 
 
 
20,108 
 
218.05 
 
 
1% 
 
 
28,725 
 
311.50 
 
   
1 Irish Adult Population aged 18-65: 2.87 million 
 
4. DISCUSSION 
The aim of this study was to estimate the direct health care costs of BPD in Ireland. The 
results of the analysis reveal that the total direct health care cost to the HSE for providing 
care to a BPD patient is €10,844 annually. An examination of the breakdown of the total cost 
of care to the health care provider reveals that hospitalisations account for almost half (51%), 
and mental health services (AMHS) for almost a third (30%) of direct health care costs. The 
remainder of costs comprise emergency and ambulatory care (7%) and medication (12%).   
 
It is important to emphasise again that the perspective of this study is quite narrow, in that 
only direct health care costs for persons with BPD in Ireland are addressed. For instance, 
other relevant costs such as those outside (mental) health care like productivity costs of the 
patients and of informal care are not considered in our analysis. Furthermore, it should also 
be noted that the overall COI estimates are calculated on the assumption that all individuals 
aged 18-65 with BPD are engaging with the health services. However, given the complexities 
of this condition it is likely that many individuals have yet to be diagnosed, some do not 
engage with services, while others may be attending primary care practitioners. This is no 
doubt a major limitation of this type of research, and suggests that the costs reported in this 
paper be treated with a degree of caution. In addition, data on resource use where participants 
engage with mental health services outside their primary service is not captured in this study, 
potentially underestimating BPD treatment costs. It is also important to also acknowledge 
that it is not only people with a formal diagnosis of BPD that generate costs to the health 
system. A recent paper on prevalence rates of BPD symptoms reports that patients with 
subthreshold BPD are intensive users of health resources (ten Have et al, 2016).  
Furthermore, in extrapolating from six months to 12 months to estimate annual resource 
utilisation, we do not account for seasonality or other factors, which may result in over or 
under estimating costs.  
 
A strength of this study lies in the data collection methods. Rather than relying on self-
reported resource utilisation from participants, data was extracted from participants’ clinical 
files by their lead treating clinician. It is unlikely that study participants would be able to 
reliably provide information retrospectively about resource utilisation given that individuals 
with a BPD diagnosis may have multiple service contacts in any one week (Bender et al., 
2006, Zanarini et al., 2001), and the study period spans across a six-month timeframe. Data in 
the clinical file is factual information based on each individual’s contact with mental health 
services (acute inpatient, outpatient and emergency department). As this study examines the 
cost of BPD only (excludes other unrelated resource use), the lead clinicians are best placed 
to accurately report on mental health services resource use in the absence of a national 
integrated health information system. This approach increases the reliability and verifiability 
of the data, which in turn improves the accuracy of the analysis.   
 
In Ireland, there is a dearth of unit cost data. While hospital admissions are covered by case-
mix, there is no accurate unit cost data for community mental health services. The absence of 
this data is a considerable constraint to research and decision-making in the area of 
community mental health services in Ireland. This paper contributes to the limited literature 
in Ireland on resource use and costs in community mental health services.  
 
There can be considerable inconsistencies in the way in which COI studies are conducted. In 
addition, some studies are far from transparent in describing the data employed and reporting 
the analysis undertaken. These shortcomings limit the usefulness and comparability of COI 
studies. To overcome these limitations, we follow guidelines from Larg and Moss (2011) in 
reporting and evaluating COI studies. These guidelines provide a standardized appraisal tool 
which encourages greater transparency of reporting. 
 
While there is an absence of COI studies of BPD in Ireland, previous COI studies for BPD 
across Europe reported average total costs ranging from €11,308 in Spain to €16,852 in the 
Netherlands (Salvador-Carulla et al., 2014, Soeteman et al., 2008, van Asselt et al., 2007). 
These studies also included non-health care costs, such as domestic help, addiction treatment, 
prison, and sheltered employment, and indirect costs such as informal care, sick leave and 
out-of-pocket expenses. As discussed, our analysis focused on direct health care costs. 
Therefore, comparisons with these Dutch and Spanish studies in respect of direct health care 
costs only are more appropriate.  
 
Practices for treating BPD vary across jurisdictions. For example, the analysis in the current 
study reveals that in an Irish setting, hospitalisations consume the most resources, which is 
similar to the Netherlands (van Asselt et al., 2007), whereas in Spain, spend on medications 
accounts for the majority of direct health care costs (Salvador-Carulla et al., 2014). The 
current study reveals that hospitalisation (51%) and medication (12%) account for 63% of 
direct health care spend in Ireland. General clinical recommendations for the treatment of 
BPD such as those advocated by the National Institute for Health and Care Excellence (2009) 
and the American Psychiatric Association (2005) advise that the primary treatment for BPD 
is psychotherapy, preferably in outpatient and day care settings, while hospitalisation and 
medication have a role in symptom management only (Departament de Salut, 2011, National 
Institute for Health and Care Excellence, 2009, Oldham, 2005 ). The results of the current 
study, as well as those in other jurisdictions, indicate a high proportion of costs for 
hospitalisation and medication use. Country-specific COI studies for BPD are vital to 
determine how resources are currently being allocated and whether such resource allocations 
are in line with best practice treatments for BPD.  
 
COI studies such as the current study can be employed to inform economic evaluations of 
specific treatments by providing nationally representative evidence on treatment as usual. 
This is of particular importance in the absence of standard randomised control trials, owing to 
lack of clinical equipoise between treatment-as-usual and evidence-based treatments. It is 
envisaged that our findings on the costs of treating BPD can be used alongside studies 
investigating the effectiveness of evidence-based treatments for BPD, such as DBT, schema 
therapy, mentalisation based therapy or transference focused psychotherapy (Departament de 
Salut, 2011, Stoffers et al., 2012). DBT is the recommended evidence-based treatment for 
persons with BPD (Government of Ireland, 2006), and is currently being implemented in 
Ireland through the National DBT Project (Flynn et al., 2018b).  Furthermore, these future 
studies can then inform the development of national guidelines that promote effective and 
cost-effective treatments for BPD, and inform budgeting and resource allocation decisions. 
This can present policy-makers with considerable challenges, particularly when health 
budgets are allocated between acute hospital services, medications and non-acute services 
etc, as is the case in Ireland.2  This necessitates budget adjustments so as to transfer the 
savings from acute services and medication budgets to fund the investment required to 
deliver interventions such as those recommended in mental health services.   
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